Which antiarrhythmic drug has a metabolite with the same pharmacologic action?

Study for the Ciulla Clinical Chemistry Test. Enhance your knowledge with flashcards and multiple-choice questions. Prepare for the exam with comprehensive study materials and detailed explanations for each question.

Multiple Choice

Which antiarrhythmic drug has a metabolite with the same pharmacologic action?

Explanation:
Some antiarrhythmics are converted into active metabolites that continue to exert the same therapeutic effect. Procainamide is metabolized to N-acetylprocainamide (NAPA), an active metabolite that retains antiarrhythmic activity. NAPA contributes to the overall action by prolonging the action potential duration, mainly through potassium-channel effects, which is a shared aspect of suppressing abnormal rhythms. Because this metabolite remains pharmacologically active, it can influence both efficacy and risk (for example, QT prolongation and torsades de pointes), especially in individuals who acetylate slowly. This is why procainamide is the drug whose metabolite has the same antiarrhythmic action as the parent drug.

Some antiarrhythmics are converted into active metabolites that continue to exert the same therapeutic effect. Procainamide is metabolized to N-acetylprocainamide (NAPA), an active metabolite that retains antiarrhythmic activity. NAPA contributes to the overall action by prolonging the action potential duration, mainly through potassium-channel effects, which is a shared aspect of suppressing abnormal rhythms. Because this metabolite remains pharmacologically active, it can influence both efficacy and risk (for example, QT prolongation and torsades de pointes), especially in individuals who acetylate slowly. This is why procainamide is the drug whose metabolite has the same antiarrhythmic action as the parent drug.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy